Aug 17, 2018

EMERGO SUMMARY OF KEY POINTS:

  • US FDA is delaying GUDID submission requirements for some combination products by one year, to 2019.
  • The delay impacts combination products that undergo premarket review by the Center for Drug Evaluation and Research (CDER).
  • The latest GUDID submission data does not deviate from trends first identified by FDA in March 2018.

FDA GUDID compliance delay for combination productsThe US Food and Drug Administration is pushing back Unique Device Identification (UDI) compliance deadlines for certain combination products by one year, to September 24, 2019. The agency has also provided updated information on GUDID entries as of August 2, 2018.

Compliance delay for CDER-reviewed combination products

According to a letter from the FDA, the delay affects drug-device and biologic-device combination products that undergo premarket review by the agency’s Center for Drug Evaluation and Research (CDER); such devices had faced a September 24, 2018 deadline for meeting UDI labeling and Global Unique Device Identification Database (GUDID) requirements, but now have until September 2019 to comply with GUDID rules. (The September 2018 deadline for UDI labeling requirements still applies to these devices.)

 “We are deploying enhancements to GUDID to better accommodate data submissions of combination products that are reviewed by CDER and contain device constituents,” explains the letter from FDA.

Latest GUDID submission data

FDA also recently published new data on GUDID records and submissions. As of August 2, 2018, about 1.8 million medical device records have been submitted into the database.

Additional data published by FDA include:

  • More than 80% of GUDID records pertain to Class II medical devices;
  • More than 40% of GUDID records are for implantable devices, systems and accessories;
  • More than 35% of product codes in GUDID are for orthopedic specialties, followed by dental (nearly 15%) and general and plastic surgery (more than 10%).

These figures are in line with those first reported by FDA in March 2018.

Learn more about US FDA UDI and GUDID regulatory requirements:

Author

  • Stewart Eisenhart

Related

US FDA Preps Enhancements to Global Unique Device Identification Database (GUDID)

EMERGO SUMMARY OF KEY POINTS:

  • US FDA will release Global Unique Device Identification Database (GUDID) information including premarket submission and supplement numbers to the public in summer 2018.
  • Medical device registrants should familiarize themselves with FDA plans and review their own confidentiality designations immediately.
  • FDA will begin releasing GUDID data to the public in June 2018.
Read more

FDA: GUDID Data Primarily from Class II and Implantable Medical Devices (So Far)

EMERGO SUMMARY OF KEY POINTS:

  • The FDA GUDID database now has more than 1.6 million records of medical devices registered for sale in the US.
  • Most GUDID data is from Class II devices, and almost half of GUDID records cover implantable devices.
  • So far, orthopedic devices account for 35% of GUDID device records.
Read more

FDA Delays Post-market Safety Reporting Requirements for Combination Products

EMERGO SUMMARY OF KEY POINTS:

  • Postponed FDA enforcement of post-market safety reporting rules (PMSR) for combination products
  • Delay allows combination product applicants more time to implement appropriate reporting and recordkeeping systems and procedures
Read more

FDA Updates PMA and 510(k) Refuse to Accept Policy for Combination Products

EMERGO SUMMARY OF KEY POINTS:

  • US FDA has updated its 510(k) Refuse to Accept and Premarket Approval acceptance policies for combination product submissions.
  • The updated guidances include new requirements for drug patent and exclusivity information.
Read more

Have questions on what Emergo can do for you?

CONTACT US